Koen Augustyns

Wilrijk, VLG 2610, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications

Correction to "Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP)".

Correction to "Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP)".

Journal: ACS medicinal chemistry letters
Published: February 24, 2026

Vectorized ULK1/2 and VPS34 Inhibitors for Tissue-Selective Autophagy Inhibition in Oncology.

Vectorized ULK1/2 and VPS34 Inhibitors for Tissue-Selective Autophagy Inhibition in Oncology.

Journal: Journal of medicinal chemistry
Published: January 26, 2026

Selective and Orally Bioavailable Dipeptidyl Peptidase 9 Inhibitors with Potent Pyroptosis Induction Properties.

Selective and Orally Bioavailable Dipeptidyl Peptidase 9 Inhibitors with Potent Pyroptosis Induction Properties.

Journal: Journal of medicinal chemistry
Published: October 29, 2025

Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential.

Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential.

Journal: Journal of medicinal chemistry
Published: October 14, 2025

Biarylacetamides: a novel class of late-stage autophagy inhibitors.

Biarylacetamides: a novel class of late-stage autophagy inhibitors.

Journal: Autophagy reports
Published: September 18, 2025

Author Correction: Targeting ferroptosis protects against experimental (multi)organ dysfunction and death.

Author Correction: Targeting ferroptosis protects against experimental (multi)organ dysfunction and death.

Journal: Nature communications
Published: September 18, 2025

Ferroptosis inhibition enhances liver and lung graft function.

Ferroptosis inhibition enhances liver and lung graft function.

Journal: Cell
Published: July 24, 2025

Using protease inhibitors to prevent intraperitoneal adhesions: effects of nafamostat mesylate, UAMC-00050, GM6001, and enoxaparin in the cecal ligation and puncture model and the ischemic button model.

Using protease inhibitors to prevent intraperitoneal adhesions: effects of nafamostat mesylate, UAMC-00050, GM6001, and enoxaparin in the cecal ligation and puncture model and the ischemic button model.

Journal: Surgery today
Published: July 02, 2025

Synthesis and Application of Activity-Based Probes for Serine Proteases.

Synthesis and Application of Activity-Based Probes for Serine Proteases.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: June 14, 2025

Highly potent dipeptidyl peptidase 8/9 (DPP8/9) inhibitors designed via relative binding free energy calculations.

Highly potent dipeptidyl peptidase 8/9 (DPP8/9) inhibitors designed via relative binding free energy calculations.

Journal: European journal of medicinal chemistry
Published: May 06, 2025

Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases.

Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases.

Journal: Journal of medicinal chemistry
Published: February 06, 2025

Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease.

Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease.

Journal: Cell death and differentiation
Published: May 28, 2024
Showing 1-12 of 110

Last Updated: 09/26/2026